At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 30 enrolled
Drug / intervention
Ivabradinedrug
Likely dose
Ivabradine 5.0 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Open-label, Single-arm, Study Assessing the Efficacy and Safety of Ivabradine (Corlanor) in African-American/Black Subjects With Heart Failure and Left Ventricular Systolic Dysfunction
In Brief
A Phase 4 clinical trial evaluating Ivabradine for Heart Failure (HF). Completed, enrolled 30 participants across 3 sites.
Detailed Summary
This study is a prospective, open-label, single-arm intervention study in African-American/Black subjects with heart failure and reduced ejection fraction (HFrEF). There will be a 7-day screening period, a 57-day open-label treatment period, and a safety follow-up at day 87 or 30 days after the last administration of the investigational product.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHeart Failure (HF)
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
201820192020202120222023202420252026
Enrollment StartSep 2017
First PostedMar 2018
Primary CompletionApr 2019
Study CompletionMay 2019
TodayJul 2026
First PostedMar 7, 2018
Enrollment StartSep 28, 2017
Primary CompletionApr 19, 2019
Study CompletionMay 20, 2019
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 8.3 years ago
Interventions
Ivabradinedrug
Film-coated tablets taken orally with food twice a day. Tablets supplied in strengths of 5.0 mg and 7.5 mg. 5.0 tablets were split into equal halves for dosages of 2.5 mg.